Biopsy Methods for Prostate Cancer
(PREVENT Trial)
Trial Summary
What is the purpose of this trial?
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer. This randomized controlled trial will be the first prospective study to evaluate in-office transperineal MRI targeted prostate biopsy. The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.
Research Team
Jim C Hu, MD MPH
Principal Investigator
Weill Cornell Medicine, NewYork-Presbyterian
Eligibility Criteria
This trial is for men over 18 who have never had a prostate biopsy and are willing to follow the study rules. It's not for those with certain metal implants, claustrophobia, pacemakers, severe kidney issues, very high PSA levels if previously biopsied, past prostate cancer treatments, current serious infections or recent prostatitis.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Antibiotic (prophylaxis) (Antibiotic)
- Transperineal MRI-guided prostate biopsy (Procedure)
- Transrectal MRI-guided prostate biopsy (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator